LATEST NEWS

Changing the radiation and immune-oncology paradigm with the radioenhancer NBTXR3: overcoming resistance to anti-PD-1 blockade from the bench to the clinic

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.